drugset

drugset / Trial / NCT00372775

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

NCT00372775 ↗

Phase 2 Completed 66 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases.

Timeline

Start: 2007-03
Primary completion: 2009-12
Completion: 2009-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	37.5 mg	Oral

Indications